uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q22.457 | Q22 | What is Nymalize? | Nymalize, also known generically as Nimodipine, was approved by the FDA in 1988 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) blocker and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nymalize%" OR LOWER(tradeNames_string) LIKE "%nymalize%" OR LOWER(drugSynonyms_string) LIKE "%nymalize%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_960', 'tradeNames_string': 'Nimodipine, Nimotop, Nymalize', 'drugName': 'Nimodipine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mineralocorticoid receptor antagonist', 'linkedDiseasesDrug_string': 'Poisoning (EFO_0008546), Stroke (EFO_0000712), Brain Aneurysm (EFO_0003870), Infertility (EFO_0000545), Cardiovascular Disease (EFO_0000319), Subarachnoid Hemorrhage (EFO_0000713), Cocaine Dependence (EFO_0002610), Muscle Cramp (EFO_0009846), Cerebrovascular Disorder (EFO_0003763), Schizophrenia (MONDO_0005090), Schwannoma (EFO_0000693)', 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1988, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_961', 'tradeNames_string': 'Nimodipine, Nimotop, Nymalize', 'drugName': 'Nimodipine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated L-type calcium channel blocker', 'linkedDiseasesDrug_string': 'Poisoning (EFO_0008546), Stroke (EFO_0000712), Brain Aneurysm (EFO_0003870), Infertility (EFO_0000545), Cardiovascular Disease (EFO_0000319), Subarachnoid Hemorrhage (EFO_0000713), Cocaine Dependence (EFO_0002610), Muscle Cramp (EFO_0009846), Cerebrovascular Disorder (EFO_0003763), Schizophrenia (MONDO_0005090), Schwannoma (EFO_0000693)', 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1988, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.435 | Q22 | What is Singulair? | Singulair, also known generically as Montelukast, was approved by the FDA in 1998 to treat Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%singulair%" OR LOWER(tradeNames_string) LIKE "%singulair%" OR LOWER(drugSynonyms_string) LIKE "%singulair%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2453', 'tradeNames_string': 'Montelukast sodium, Singulair', 'drugName': 'Montelukast Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Cysteinyl leukotriene receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Rhinitis (EFO_0008521), Asthma (MONDO_0004979), Sepsis (HP_0100806), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Neonatal Sepsis (HP_0040187), Chronic Obstructive Pulmonary Disease (EFO_0000341), Eosinophilic Esophagitis (EFO_0004232), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Bronchiolitis (HP_0011950)', 'newLinkedTargets_string': 'CYSLTR1 (ENSG00000173198)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2189', 'tradeNames_string': 'Singulair', 'drugName': 'Montelukast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Cysteinyl leukotriene receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Pain (EFO_0003843), Cough (HP_0012735), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Bronchiolitis (HP_0011950), Seasonal Allergic Rhinitis (EFO_0003956), Dengue Hemorrhagic Fever (EFO_0004227), Acute Lymphoblastic Leukemia (EFO_0000220), Non-Alcoholic Steatohepatitis (EFO_1001249), Acute Myeloid Leukemia (EFO_0000222), Immune System Disease (EFO_0000540), Asthma (MONDO_0004979), Respiratory System Disease (EFO_0000684), Premature Birth (EFO_0003917), Sepsis (HP_0100806), Rhinitis, Allergic, Perennial (EFO_1001417), Sickle Cell Anemia (MONDO_0011382), Neonatal Sepsis (HP_0040187), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Obstructive Sleep Apnea (EFO_0003918), Rheumatoid Arthritis (EFO_0000685), Wheezing (EFO_0009715), Sleep Apnea (EFO_0003877), Hiv Infection (EFO_0000764), Diabetic Nephropathy (EFO_0000401), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694), Rhinitis (EFO_0008521)', 'newLinkedTargets_string': 'CYSLTR1 (ENSG00000173198)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.6 | Q22 | What is Calquence? | Calquence, also known generically as Acalabrutinib Maleate, was approved by the FDA in 2022 to treat chronic lymphocytic leukemia and Mantle cell lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%calquence%" OR LOWER(tradeNames_string) LIKE "%calquence%" OR LOWER(drugSynonyms_string) LIKE "%calquence%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_593', 'tradeNames_string': 'Calquence', 'drugName': 'Acalabrutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase BTK inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Infectious Disease (EFO_0005741), Food Allergy (EFO_1001890), Ovarian Cancer (MONDO_0008170), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Rheumatoid Arthritis (EFO_0000685), Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6297', 'tradeNames_string': 'Calquence', 'drugName': 'Acalabrutinib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase BTK inhibitor', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Mantle Cell Lymphoma (EFO_1001469)', 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.692 | Q22 | What is Erivedge? | Erivedge, also known generically as Vismodegib, was approved by the FDA in 2012 to treat cancer, neoplasm, basal cell carcinoma, and skin basal cell carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%erivedge%" OR LOWER(tradeNames_string) LIKE "%erivedge%" OR LOWER(drugSynonyms_string) LIKE "%erivedge%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5550', 'tradeNames_string': 'Erivedge', 'drugName': 'Vismodegib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Smoothened homolog inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nevoid Basal Cell Carcinoma Syndrome (MONDO_0007187), Multiple Myeloma (EFO_0001378), Medulloblastoma (EFO_0002939), Central Nervous System Cancer (EFO_0000326), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Mesenchymal Chondrosarcoma (EFO_1001041), Breast Carcinoma (EFO_0000305), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Myelofibrosis (MONDO_0044903), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Skin Basal Cell Carcinoma (MONDO_0005341), Neoplasm (EFO_0000616), Meningioma (MONDO_0016642), Clear Cell Chondrosarcoma (MONDO_0003684), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897)', 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.46 | Q22 | What is Cinvanti? | Cinvanti, also known generically as Aprepitant, was approved by the FDA in 2003 to treat Nausea and vomiting, Nausea, cancer, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cinvanti%" OR LOWER(tradeNames_string) LIKE "%cinvanti%" OR LOWER(drugSynonyms_string) LIKE "%cinvanti%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1299', 'tradeNames_string': 'Aprepitant, Cinvanti, Emend', 'drugName': 'Aprepitant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Gastroparesis (EFO_1000948), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Nausea And Vomiting (HP_0002017), Non-Small Cell Lung Carcinoma (EFO_0003060), Major Depressive Disorder (MONDO_0002009), Vomiting (HP_0002013), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.404 | Q22 | What is Namenda Xr? | Namenda Xr, also known generically as Memantine Hydrochloride, was approved by the FDA in 2003 to treat Dementia and Alzheimer disease. It is a small molecule therapy that acts as a(n) negative allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%namenda xr%" OR LOWER(tradeNames_string) LIKE "%namenda xr%" OR LOWER(drugSynonyms_string) LIKE "%namenda xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4606', 'tradeNames_string': 'Akatinol, Ebixa, Marixino, Memantine, Memantine hydrochloride, Namenda, Namenda xr, Nemdatine, Valios', 'drugName': 'Memantine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'negative allosteric modulator', 'drugMechanismOfAction': 'Glutamate [NMDA] receptor negative allosteric modulator', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Gliosarcoma (EFO_1001465), Intracranial Subdural Hematoma (EFO_1001801), Alzheimer Disease (MONDO_0004975), Frontotemporal Dementia (MONDO_0017276), Amyotrophic Lateral Sclerosis (MONDO_0004976), Asperger Syndrome (EFO_0003757), Sickle Cell Anemia (MONDO_0011382), Dementia (HP_0000726), Central Nervous System Cancer (EFO_0000326), Learning Disability (MONDO_0004681), Brain Neoplasm (EFO_0003833), Influenza (EFO_0007328), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.532 | Q22 | What is Folotyn? | Folotyn, also known generically as Pralatrexate, was approved by the FDA in 2009 to treat unspecified peripheral T-cell lymphoma, cancer, neoplasm, mature T-cell and NK-cell non-Hodgkin lymphoma, and T-cell non-Hodgkin lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%folotyn%" OR LOWER(tradeNames_string) LIKE "%folotyn%" OR LOWER(drugSynonyms_string) LIKE "%folotyn%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_39', 'tradeNames_string': 'Folotyn', 'drugName': 'Pralatrexate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydrofolate reductase inhibitor', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Peritoneum Cancer (MONDO_0002087), Cutaneous T-Cell Lymphoma (EFO_0002913), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'newLinkedTargets_string': 'DHFR (ENSG00000228716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.174 | Q22 | What is Sprycel? | Sprycel, also known generically as Dasatinib, was approved by the FDA in 2006 to treat acute lymphoblastic leukemia, cancer, chronic myelogenous leukemia, neoplasm, childhood cancer, childhood acute lymphoblastic leukemia, and lymphoblastic lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sprycel%" OR LOWER(tradeNames_string) LIKE "%sprycel%" OR LOWER(drugSynonyms_string) LIKE "%sprycel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4598', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4599', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4600', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4601', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4602', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'SRC inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4603', 'tradeNames_string': 'Dasatinib, Sprycel', 'drugName': 'Dasatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ephrin type-A receptor 2 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Pineoblastoma (EFO_1000475), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malt Lymphoma (EFO_0000191), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Childhood Cancer (EFO_1000654), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Brain Disease (EFO_0005774), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Systemic Mastocytosis (MONDO_0016586), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.17 | Q22 | What is Ventolin Hfa? | Ventolin Hfa, also known generically as Albuterol Sulfate, was approved by the FDA in 1982 to treat Bronchospasm, chronic obstructive pulmonary disease, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ventolin hfa%" OR LOWER(tradeNames_string) LIKE "%ventolin hfa%" OR LOWER(drugSynonyms_string) LIKE "%ventolin hfa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1434', 'tradeNames_string': 'Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Albuterol, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent, Combivent udvs, Ipramol steri-neb, Kentamol, Libetist, Maxivent, Proair Hfa, Proventil, Proventil Hfa, Rimasal, Salamol e-breathe, Salapin, Salbulin novolizer, Salbuvent, Salipraneb, Steri-neb salamol, Ventmax sr, Ventodisks, Ventolin, Ventolin Hfa, Ventolin cr, Ventolin e-breathe, Volmax', 'drugName': 'Albuterol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Status Asthmaticus (EFO_0008590), Pulmonary Hypertension (MONDO_0005149), Cough (HP_0012735), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Spinal Cord Injury (EFO_1001919), Bronchiolitis (HP_0011950), Idiopathic Pulmonary Arterial Hypertension (MONDO_0017147), Bronchospasm (HP_0025428), Congestive Heart Failure (EFO_0000373), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Edema (EFO_1001134), Organophosphate Poisoning (EFO_0010581), Familial Dysautonomia (Orphanet_1764), Asthma (MONDO_0004979), Memory Impairment (EFO_0001072), Tachypnea (EFO_0009840), Chronic Obstructive Pulmonary Disease (EFO_0000341), Primary Ciliary Dyskinesia (MONDO_0016575), Airway Obstruction (HP_0006536), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Allergic Disease (MONDO_0005271), Congenital Myasthenic Syndromes (Orphanet_590), Respiratory Failure (EFO_0009686), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6278', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugName': 'Albuterol Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.49 | Q22 | What is Aristada? | Aristada, also known generically as Aripiprazole Lauroxil, was approved by the FDA in 2015 to treat autism, Tourette syndrome, bipolar I disorder, major depressive disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) partial agonist and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aristada%" OR LOWER(tradeNames_string) LIKE "%aristada%" OR LOWER(drugSynonyms_string) LIKE "%aristada%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4679', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Dopamine D2 receptor partial agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4680', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4681', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Serotonin 1a (5-HT1a) receptor partial agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.682 | Q22 | What is Staxyn? | Staxyn, also known generically as Vardenafil Hydrochloride, was approved by the FDA in 2003 to treat erectile dysfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%staxyn%" OR LOWER(tradeNames_string) LIKE "%staxyn%" OR LOWER(drugSynonyms_string) LIKE "%staxyn%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4542', 'tradeNames_string': 'Levitra, Staxyn, Vardenafil hydrochloride', 'drugName': 'Vardenafil Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.646 | Q22 | What is Fotivda? | Fotivda, also known generically as Tivozanib Hydrochloride, was approved by the FDA in 2021 to treat renal cell carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fotivda%" OR LOWER(tradeNames_string) LIKE "%fotivda%" OR LOWER(drugSynonyms_string) LIKE "%fotivda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2104', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2105', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2106', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_874', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_875', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_876', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.4 | Q22 | What is Cibinqo? | Cibinqo, also known generically as Abrocitinib, was approved by the FDA in 2022 to treat Eczema and atopic eczema. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cibinqo%" OR LOWER(tradeNames_string) LIKE "%cibinqo%" OR LOWER(drugSynonyms_string) LIKE "%cibinqo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1422', 'tradeNames_string': 'Cibinqo', 'drugName': 'Abrocitinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase JAK1 inhibitor', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Liver Disease (EFO_0001421), Atopic Eczema (EFO_0000274), Kidney Disease (EFO_0003086), Food Allergy (EFO_1001890)', 'newLinkedTargets_string': 'JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.455 | Q22 | What is Tasigna? | Tasigna, also known generically as Nilotinib, was approved by the FDA in 2007 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tasigna%" OR LOWER(tradeNames_string) LIKE "%tasigna%" OR LOWER(drugSynonyms_string) LIKE "%tasigna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6060', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Graft Versus Host Disease (MONDO_0013730), Cerebellar Ataxia (MONDO_0000437), Myeloid Leukemia (MONDO_0004643), Pulmonary Arterial Hypertension (EFO_0001361), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Chronic Myelogenous Leukemia (EFO_0000339), Malignant Colon Neoplasm (MONDO_0021063), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Huntington Disease (MONDO_0007739), Acute Lymphoblastic Leukemia (EFO_0000220), Parkinson Disease (MONDO_0005180), Acute Myeloid Leukemia (EFO_0000222), Soft Tissue Sarcoma (EFO_1001968), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Schwannoma (EFO_0000693), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Chordoma (MONDO_0008978), Giant Cell Tumor (MONDO_0002171), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6061', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Graft Versus Host Disease (MONDO_0013730), Cerebellar Ataxia (MONDO_0000437), Myeloid Leukemia (MONDO_0004643), Pulmonary Arterial Hypertension (EFO_0001361), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Chronic Myelogenous Leukemia (EFO_0000339), Malignant Colon Neoplasm (MONDO_0021063), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Huntington Disease (MONDO_0007739), Acute Lymphoblastic Leukemia (EFO_0000220), Parkinson Disease (MONDO_0005180), Acute Myeloid Leukemia (EFO_0000222), Soft Tissue Sarcoma (EFO_1001968), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Schwannoma (EFO_0000693), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Chordoma (MONDO_0008978), Giant Cell Tumor (MONDO_0002171), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_435', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_436', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.418 | Q22 | What is Quillivant Xr? | Quillivant Xr, also known generically as Methylphenidate Hydrochloride, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quillivant xr%" OR LOWER(tradeNames_string) LIKE "%quillivant xr%" OR LOWER(drugSynonyms_string) LIKE "%quillivant xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_845', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_846', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.321 | Q22 | What is Truseltiq? | Truseltiq, also known generically as Infigratinib Phosphate, was approved by the FDA in 2021 to treat cholangiocarcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%truseltiq%" OR LOWER(tradeNames_string) LIKE "%truseltiq%" OR LOWER(drugSynonyms_string) LIKE "%truseltiq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3003', 'tradeNames_string': 'Truseltiq', 'drugName': 'Infigratinib Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.650 | Q22 | What is Samsca? | Samsca, also known generically as Tolvaptan, was approved by the FDA in 2009 to treat Hyponatremia, cardiovascular disease, congestive heart failure, heart failure, Polycystic Kidney Disease, and polycystic kidney disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%samsca%" OR LOWER(tradeNames_string) LIKE "%samsca%" OR LOWER(drugSynonyms_string) LIKE "%samsca%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5028', 'tradeNames_string': 'Jinarc, Jynarque, Samsca', 'drugName': 'Tolvaptan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Vasopressin V2 receptor antagonist', 'linkedDiseasesDrug_string': 'Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Cardiac Edema (EFO_1001771), Congestive Heart Failure (EFO_0000373), Inappropriate Adh Syndrome (EFO_1000982), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Hyponatremia (HP_0002902), Kidney Disease (EFO_0003086), Polycystic Kidney Disease (EFO_0008620), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Carcinoma (EFO_0000313), Nephrolithiasis (EFO_0004253), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.287 | Q22 | What is Baqsimi? | Baqsimi, also known generically as Glucagon, was approved by the FDA in 1998 to treat Hypoglycemia and diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%baqsimi%" OR LOWER(tradeNames_string) LIKE "%baqsimi%" OR LOWER(drugSynonyms_string) LIKE "%baqsimi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1857', 'tradeNames_string': 'Baqsimi, Glucagen Hypokit, Glucagon, Glucagon Emergency Kit, Gvoke hypopen, Gvoke pfs', 'drugName': 'Glucagon', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Common Cold (EFO_0007214), Familial Hyperinsulinism (MONDO_0017182), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147), Hypoglycemia (HP_0001943), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperinsulinemic Hypoglycemia (EFO_0007318)', 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.588 | Q22 | What is Vesicare Ls? | Vesicare Ls, also known generically as Solifenacin Succinate, was approved by the FDA in 2004 to treat urgency urinary incontinence and overactive bladder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vesicare ls%" OR LOWER(tradeNames_string) LIKE "%vesicare ls%" OR LOWER(drugSynonyms_string) LIKE "%vesicare ls%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1607', 'tradeNames_string': 'Solifenacin succinate, Vesicare, Vesicare ls', 'drugName': 'Solifenacin Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M2 antagonist', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Urgency Urinary Incontinence (EFO_0006865)', 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1608', 'tradeNames_string': 'Solifenacin succinate, Vesicare, Vesicare ls', 'drugName': 'Solifenacin Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Urgency Urinary Incontinence (EFO_0006865)', 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.289 | Q22 | What is Gvoke Pfs? | Gvoke Pfs, also known generically as Glucagon, was approved by the FDA in 1998 to treat Hypoglycemia and diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gvoke pfs%" OR LOWER(tradeNames_string) LIKE "%gvoke pfs%" OR LOWER(drugSynonyms_string) LIKE "%gvoke pfs%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1857', 'tradeNames_string': 'Baqsimi, Glucagen Hypokit, Glucagon, Glucagon Emergency Kit, Gvoke hypopen, Gvoke pfs', 'drugName': 'Glucagon', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Common Cold (EFO_0007214), Familial Hyperinsulinism (MONDO_0017182), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147), Hypoglycemia (HP_0001943), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperinsulinemic Hypoglycemia (EFO_0007318)', 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.684 | Q22 | What is Parsabiv? | Parsabiv, also known generically as Velcalcetide, was approved by the FDA in 2017 to treat chronic kidney disease, parathyroid disease, and secondary hyperparathyroidism. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%parsabiv%" OR LOWER(tradeNames_string) LIKE "%parsabiv%" OR LOWER(drugSynonyms_string) LIKE "%parsabiv%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3935', 'tradeNames_string': 'Parsabiv', 'drugName': 'Velcalcetide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Calcium sensing receptor agonist', 'linkedDiseasesDrug_string': 'Parathyroid Disease (EFO_0005754), Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173)', 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.229 | Q22 | What is Halaven? | Halaven, also known generically as Eribulin Mesylate, was approved by the FDA in 2010 to treat breast carcinoma, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%halaven%" OR LOWER(tradeNames_string) LIKE "%halaven%" OR LOWER(drugSynonyms_string) LIKE "%halaven%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3175', 'tradeNames_string': 'Halaven', 'drugName': 'Eribulin Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Urothelial Carcinoma (EFO_0008528), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Primary Brain Neoplasm (MONDO_0021632), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Salivary Gland Cancer (MONDO_0004669), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5604', 'tradeNames_string': 'Halaven', 'drugName': 'Eribulin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Epithelioid Hemangioendothelioma (MONDO_0015523), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Primary Brain Neoplasm (MONDO_0021632), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Solitary Fibrous Tumor (MONDO_0016238), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Salivary Gland Cancer (MONDO_0004669), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.27 | Q22 | What is Entereg? | Entereg, also known generically as Alvimopan, was approved by the FDA in 2008 to treat Constipation. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%entereg%" OR LOWER(tradeNames_string) LIKE "%entereg%" OR LOWER(drugSynonyms_string) LIKE "%entereg%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4682', 'tradeNames_string': 'Entereg', 'drugName': 'Alvimopan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mu opioid receptor antagonist', 'linkedDiseasesDrug_string': 'Fallopian Tube Cancer (MONDO_0002158), Urinary Bladder Cancer (MONDO_0001187), Constipation (HP_0002019), Peritoneum Cancer (MONDO_0002087), Ileus (MONDO_0004567), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.554 | Q22 | What is Actonel? | Actonel, also known generically as Risedronate Sodium, was approved by the FDA in 1998 to treat postmenopausal osteoporosis, osteoporosis, and Paget disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%actonel%" OR LOWER(tradeNames_string) LIKE "%actonel%" OR LOWER(drugSynonyms_string) LIKE "%actonel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4717', 'tradeNames_string': 'Actonel, Atelvia, Risedronate sodium', 'drugName': 'Risedronate Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Paget Disease (MONDO_0021165), Postmenopausal Osteoporosis (EFO_0003854), Leukemia (EFO_0000565), Lymphoma (EFO_0000574), Anorexia Nervosa (MONDO_0005351), Osteogenesis Imperfecta (MONDO_0019019)', 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1294', 'tradeNames_string': '', 'drugName': 'Risedronic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Bone Disease (EFO_0004260), Paget Disease (MONDO_0021165), Postmenopausal Osteoporosis (EFO_0003854), Prostate Cancer (MONDO_0008315), Leukemia (EFO_0000565), Menopause (EFO_0003922), Fibrous Dysplasia (MONDO_0000845), Metastatic Prostate Cancer (EFO_0000196), Renal Osteodystrophy (EFO_1001152), Lymphoma (EFO_0000574), Back Pain (HP_0003418), Lung Neoplasm (MONDO_0021117), Osteitis Deformans (EFO_0004261), Anorexia Nervosa (MONDO_0005351), Osteogenesis Imperfecta (MONDO_0019019), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.267 | Q22 | What is Gilenya? | Gilenya, also known generically as Fingolimod Hydrochloride, was approved by the FDA in 2010 to treat multiple sclerosis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gilenya%" OR LOWER(tradeNames_string) LIKE "%gilenya%" OR LOWER(drugSynonyms_string) LIKE "%gilenya%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4816', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'binding agent', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor binding agent', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4817', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor agonist', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4765', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor agonist', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Breast Carcinoma (EFO_0000305), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.51 | Q22 | What is Nuvigil? | Nuvigil, also known generically as Armodafinil, was approved by the FDA in 2007 to treat attention deficit hyperactivity disorder, obstructive sleep apnea, Sleep Disorder, narcolepsy-cataplexy syndrome, and narcolepsy. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nuvigil%" OR LOWER(tradeNames_string) LIKE "%nuvigil%" OR LOWER(drugSynonyms_string) LIKE "%nuvigil%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2926', 'tradeNames_string': 'Armodafinil, Nuvigil', 'drugName': 'Armodafinil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Malignant Glioma (MONDO_0100342), Sleep Disorder (EFO_0008568), Hypersomnia (EFO_0005246), Stroke (EFO_0000712), Narcolepsy (MONDO_0021107), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Insomnia (EFO_0004698), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.370 | Q22 | What is Tirosint? | Tirosint, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tirosint%" OR LOWER(tradeNames_string) LIKE "%tirosint%" OR LOWER(drugSynonyms_string) LIKE "%tirosint%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.233 | Q22 | What is Spravato? | Spravato, also known generically as Esketamine Hydrochloride, was approved by the FDA in 2019 to treat unipolar depression and major depressive disorder. It is a small molecule therapy that acts as a(n) negative allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spravato%" OR LOWER(tradeNames_string) LIKE "%spravato%" OR LOWER(drugSynonyms_string) LIKE "%spravato%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_817', 'tradeNames_string': 'Spravato', 'drugName': 'Esketamine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'negative allosteric modulator', 'drugMechanismOfAction': 'Glutamate [NMDA] receptor negative allosteric modulator', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Pain (EFO_0003843)', 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.38 | Q22 | What is Adzenys Xr-Odt? | Adzenys Xr-Odt, also known generically as Amphetamine, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adzenys xr-odt%" OR LOWER(tradeNames_string) LIKE "%adzenys xr-odt%" OR LOWER(drugSynonyms_string) LIKE "%adzenys xr-odt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1570', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1571', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.160 | Q22 | What is Mytesi? | Mytesi, also known generically as Crofelemer, was approved by the FDA in 2012 to treat Diarrhea and AIDS. It is a small molecule therapy that acts as a(n) inhibitor and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mytesi%" OR LOWER(tradeNames_string) LIKE "%mytesi%" OR LOWER(drugSynonyms_string) LIKE "%mytesi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2220', 'tradeNames_string': 'Fulyzaq, Mytesi, Provir, Virend', 'drugName': 'Crofelemer', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cystic fibrosis transmembrane conductance regulator inhibitor', 'linkedDiseasesDrug_string': 'Aids (EFO_0000765), Irritable Bowel Syndrome (EFO_0000555), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'CFTR (ENSG00000001626), ANO1 (ENSG00000131620)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2221', 'tradeNames_string': 'Fulyzaq, Mytesi, Provir, Virend', 'drugName': 'Crofelemer', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Anoctamin-1 blocker', 'linkedDiseasesDrug_string': 'Aids (EFO_0000765), Irritable Bowel Syndrome (EFO_0000555), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'CFTR (ENSG00000001626), ANO1 (ENSG00000131620)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.241 | Q22 | What is Femtrace? | Femtrace, also known generically as Estradiol Acetate, was approved by the FDA in 2003 to treat menopause and Atrophy. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%femtrace%" OR LOWER(tradeNames_string) LIKE "%femtrace%" OR LOWER(drugSynonyms_string) LIKE "%femtrace%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3260', 'tradeNames_string': 'Femring, Femtrace', 'drugName': 'Estradiol Acetate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Atrophy (EFO_1000096), Menopause (EFO_0003922)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.677 | Q22 | What is Rinvoq? | Rinvoq, also known generically as Upadacitinib, was approved by the FDA in 2019 to treat immune system disease and rheumatoid arthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rinvoq%" OR LOWER(tradeNames_string) LIKE "%rinvoq%" OR LOWER(drugSynonyms_string) LIKE "%rinvoq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4653', 'tradeNames_string': 'Rinvoq', 'drugName': 'Upadacitinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Janus Kinase (JAK) inhibitor', 'linkedDiseasesDrug_string': "Temporal Arteritis (EFO_1001209), Vitiligo (EFO_0004208), Crohn'S Disease (EFO_0000384), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Hidradenitis Suppurativa (EFO_1000710), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685), Ulcerative Colitis (EFO_0000729), Immune System Disease (EFO_0000540)", 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.380 | Q22 | What is Qbrelis? | Qbrelis, also known generically as Lisinopril, was approved by the FDA in 1987 to treat cardiovascular disease, congestive heart failure, diabetes mellitus, hypertension, myocardial infarction, stroke, and heart failure. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qbrelis%" OR LOWER(tradeNames_string) LIKE "%qbrelis%" OR LOWER(drugSynonyms_string) LIKE "%qbrelis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_656', 'tradeNames_string': 'Acemin, Carace, Lisinopril, Lisopress, Prinivil, Qbrelis, Zestril', 'drugName': 'Lisinopril', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Angiotensin-converting enzyme inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Congestive Heart Failure (EFO_0000373), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.376 | Q22 | What is Tradjenta? | Tradjenta, also known generically as Linagliptin, was approved by the FDA in 2011 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tradjenta%" OR LOWER(tradeNames_string) LIKE "%tradjenta%" OR LOWER(drugSynonyms_string) LIKE "%tradjenta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_745', 'tradeNames_string': 'Tradjenta, Trajenta', 'drugName': 'Linagliptin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Respiratory System Disease (EFO_0000684), Esophageal Carcinoma (EFO_0002916), Gastric Adenocarcinoma (EFO_0000503), Non-Small Cell Lung Carcinoma (EFO_0003060), Covid-19 (MONDO_0100096), Hypertension (EFO_0000537), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.178 | Q22 | What is Firmagon? | Firmagon, also known generically as Degarelix, was approved by the FDA in 2008 to treat neoplasm. It is a protein therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%firmagon%" OR LOWER(tradeNames_string) LIKE "%firmagon%" OR LOWER(drugSynonyms_string) LIKE "%firmagon%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6054', 'tradeNames_string': 'Firmagon', 'drugName': 'Degarelix Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1491', 'tradeNames_string': 'Firmagon', 'drugName': 'Degarelix', 'drugMolecularType': 'Protein', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Benign Prostatic Hyperplasia (EFO_0000284), Covid-19 (MONDO_0100096), Prostate Neoplasm (MONDO_0021259), Male Breast Carcinoma (EFO_0006861), Metastatic Prostate Cancer (EFO_0000196), Infertility (EFO_0000545), Endometriosis (EFO_0001065), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.598 | Q22 | What is Alsuma? | Alsuma, also known generically as Sumatriptan Succinate, was approved by the FDA in 1992 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alsuma%" OR LOWER(tradeNames_string) LIKE "%alsuma%" OR LOWER(drugSynonyms_string) LIKE "%alsuma%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1609', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1610', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.487 | Q22 | What is Xtampza Er? | Xtampza Er, also known generically as Oxycodone, was approved by the FDA in 1950 to treat Chronic pain, pain, drug dependence, and substance abuse. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xtampza er%" OR LOWER(tradeNames_string) LIKE "%xtampza er%" OR LOWER(drugSynonyms_string) LIKE "%xtampza er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6046', 'tradeNames_string': 'Oxycontin, Proladone, Xtampza er', 'drugName': 'Oxycodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Genital Neoplasm, Female (EFO_1001331), Substance Abuse (MONDO_0002491), Pain (EFO_0003843), Injury (EFO_0000546), Colorectal Carcinoma (EFO_1001951), Nephrolithiasis (EFO_0004253), Spinal Cord Injury (EFO_1001919), Hypospadias (EFO_0004209), Preeclampsia (EFO_0000668), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Parkinson Disease (MONDO_0005180), Neuropathic Pain (EFO_0005762), Respiratory Depression (EFO_0009842), Pruritus (HP_0000989), Restless Legs Syndrome (EFO_0004270), Sinusitis (EFO_0007486), Nutritional Disorder (EFO_0001069), Neck Pain (HP_0030833), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Joint Disease (EFO_1000999), Opioid Dependence (EFO_0005611), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.520 | Q22 | What is Oraverse? | Oraverse, also known generically as Phentolamine Mesylate, was approved by the FDA in 1952 to treat adrenal gland pheochromocytoma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oraverse%" OR LOWER(tradeNames_string) LIKE "%oraverse%" OR LOWER(drugSynonyms_string) LIKE "%oraverse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3568', 'tradeNames_string': 'Oraverse, Phentolamine mesylate, Regitine, Rogitine', 'drugName': 'Phentolamine Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Cardiovascular Disease (EFO_0000319), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1952, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.197 | Q22 | What is Tecfidera? | Tecfidera, also known generically as Dimethyl Fumarate, was approved by the FDA in 2013 to treat immune system disease and multiple sclerosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tecfidera%" OR LOWER(tradeNames_string) LIKE "%tecfidera%" OR LOWER(drugSynonyms_string) LIKE "%tecfidera%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3182', 'tradeNames_string': 'Tecfidera', 'drugName': 'Dimethyl Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Kelch-like ECH-associated protein 1 inhibitor', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Gliosarcoma (EFO_1001465), Intracerebral Hemorrhage (EFO_0005669), Chronic Lymphocytic Leukemia (EFO_0000095), Ischemic Stroke (HP_0002140), Multiple Sclerosis (MONDO_0005301), Chronic Progressive Multiple Sclerosis (EFO_0003840), Psoriatic Arthritis (EFO_0003778), Severe Acute Respiratory Syndrome (EFO_0000694), Rheumatoid Arthritis (EFO_0000685), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Obstructive Sleep Apnea (EFO_0003918), Cutaneous T-Cell Lymphoma (EFO_0002913), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520)', 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.600 | Q22 | What is Sumavel Dosepro? | Sumavel Dosepro, also known generically as Sumatriptan Succinate, was approved by the FDA in 1992 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sumavel dosepro%" OR LOWER(tradeNames_string) LIKE "%sumavel dosepro%" OR LOWER(drugSynonyms_string) LIKE "%sumavel dosepro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1609', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1610', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.608 | Q22 | What is Vyndaqel? | Vyndaqel, also known generically as Tafamidis Meglumine, was approved by the FDA in 2019 to treat cardiomyopathy, amyloidosis, and AL amyloidosis. It is a small molecule therapy that acts as a(n) stabiliser. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyndaqel%" OR LOWER(tradeNames_string) LIKE "%vyndaqel%" OR LOWER(drugSynonyms_string) LIKE "%vyndaqel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_8', 'tradeNames_string': 'Vyndaqel', 'drugName': 'Tafamidis Meglumine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'stabiliser', 'drugMechanismOfAction': 'Transthyretin stabiliser', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3770', 'tradeNames_string': 'Vyndamax, Vyndaqel', 'drugName': 'Tafamidis', 'drugMolecularType': 'Small molecule', 'drugActionType': 'stabiliser', 'drugMechanismOfAction': 'Transthyretin stabiliser', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.431 | Q22 | What is Exkivity? | Exkivity, also known generically as Mobocertinib Succinate, was approved by the FDA in 2021 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%exkivity%" OR LOWER(tradeNames_string) LIKE "%exkivity%" OR LOWER(drugSynonyms_string) LIKE "%exkivity%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1983', 'tradeNames_string': 'Exkivity', 'drugName': 'Mobocertinib Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.451 | Q22 | What is Nevanac? | Nevanac, also known generically as Nepafenac, was approved by the FDA in 2005 to treat inflammation, eye inflammation, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nevanac%" OR LOWER(tradeNames_string) LIKE "%nevanac%" OR LOWER(drugSynonyms_string) LIKE "%nevanac%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5261', 'tradeNames_string': 'Ilevro, Nepafenac, Nevanac', 'drugName': 'Nepafenac', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Eye Inflammation (EFO_0005752), Miosis (HP_0000616), Inflammation (MP_0001845), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.454 | Q22 | What is Nicorette? | Nicorette, also known generically as Nicotine Polacrilex, was approved by the FDA in 1984 to treat nicotine dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nicorette%" OR LOWER(tradeNames_string) LIKE "%nicorette%" OR LOWER(drugSynonyms_string) LIKE "%nicorette%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5052', 'tradeNames_string': 'Commit, Nicorette, Nicorette (mint), Nicotine polacrilex, Thrive', 'drugName': 'Nicotine Polacrilex', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Neuronal acetylcholine receptor; alpha4/beta2 agonist', 'linkedDiseasesDrug_string': 'Nicotine Dependence (EFO_0003768), Depressive Disorder (MONDO_0002050)', 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_687', 'tradeNames_string': 'Habitrol, Nicabate, Nicoderm, Nicoderm cq, Nicopass, Nicopatch, Nicorette invisi, Nicotine, Nicotinell classic, Nicotinell support, Nicotinell tts 10, Nicotinell tts 20, Nicotinell tts 30, Nicotrol, Nicotrol Inhaler, Nicotrol NS, Niquitin, Niquitin clr, Niquitin minis cherry, Niquitin minis mint, Niquitin minis orange, Niquitin mint, Niquitin pre-quit, Niquitin strips mint, Prostep, Stoppers, Stubit', 'drugName': 'Nicotine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Neuronal acetylcholine receptor; alpha4/beta2 agonist', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Aging (GO_0007568), Nicotine Dependence (EFO_0003768), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), In Situ Carcinoma (MONDO_0004647), Alcohol Drinking (EFO_0004329), Memory Impairment (EFO_0001072), Pulmonary Sarcoidosis (DOID_13406), Chronic Obstructive Pulmonary Disease (EFO_0000341), Substance Dependence (MONDO_0004938), Depressive Disorder (MONDO_0002050), Carcinoma (EFO_0000313), Cervical Cancer (MONDO_0002974), Sarcoidosis (MONDO_0019338), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Lung Cancer (MONDO_0008903), Heart Failure (EFO_0003144), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Schizophrenia (MONDO_0005090), Severe Acute Respiratory Syndrome (EFO_0000694)', 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.681 | Q22 | What is Levitra? | Levitra, also known generically as Vardenafil Hydrochloride, was approved by the FDA in 2003 to treat erectile dysfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levitra%" OR LOWER(tradeNames_string) LIKE "%levitra%" OR LOWER(drugSynonyms_string) LIKE "%levitra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2264', 'tradeNames_string': 'Levitra', 'drugName': 'Vardenafil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Pulmonary Hypertension (MONDO_0005149), Ischemia Reperfusion Injury (EFO_0002687), Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Raynaud Disease (EFO_1001145), Tinnitus (HP_0000360), Cystic Fibrosis (MONDO_0009061)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4542', 'tradeNames_string': 'Levitra, Staxyn, Vardenafil hydrochloride', 'drugName': 'Vardenafil Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.587 | Q22 | What is Xyrem? | Xyrem, also known generically as Sodium Oxybate, was approved by the FDA in 2002 to treat narcolepsy-cataplexy syndrome and narcolepsy. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xyrem%" OR LOWER(tradeNames_string) LIKE "%xyrem%" OR LOWER(drugSynonyms_string) LIKE "%xyrem%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4208', 'tradeNames_string': 'Xyrem', 'drugName': 'Sodium Oxybate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'GABA-B receptor agonist', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Sleep Disorder (EFO_0008568), Essential Tremor (EFO_0003108), Pain (EFO_0003843), Alternating Hemiplegia Of Childhood (MONDO_0016241), Spasmodic Dystonia (MONDO_0000485), Parkinson Disease (MONDO_0005180), Narcolepsy (MONDO_0021107), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Fibromyalgia (EFO_0005687), Eating Disorder (EFO_0005203), Tremor (HP_0001337)', 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4894', 'tradeNames_string': '', 'drugName': 'Oxybate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'GABA-B receptor agonist', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Sleep Disorder (EFO_0008568), Essential Tremor (EFO_0003108), Alternating Hemiplegia Of Childhood (MONDO_0016241), Pain (EFO_0003843), Spasmodic Dystonia (MONDO_0000485), Narcolepsy (MONDO_0021107), Parkinson Disease (MONDO_0005180), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Fibromyalgia (EFO_0005687), Eating Disorder (EFO_0005203), Tremor (HP_0001337)', 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.606 | Q22 | What is Vyndamax? | Vyndamax, also known generically as Tafamidis, was approved by the FDA in 2019 to treat cardiomyopathy, amyloidosis, and AL amyloidosis. It is a small molecule therapy that acts as a(n) stabiliser. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyndamax%" OR LOWER(tradeNames_string) LIKE "%vyndamax%" OR LOWER(drugSynonyms_string) LIKE "%vyndamax%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3770', 'tradeNames_string': 'Vyndamax, Vyndaqel', 'drugName': 'Tafamidis', 'drugMolecularType': 'Small molecule', 'drugActionType': 'stabiliser', 'drugMechanismOfAction': 'Transthyretin stabiliser', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.68 | Q22 | What is Lyvispah? | Lyvispah, also known generically as Baclofen, was approved by the FDA in 1977 to treat Spasticity, Rigidity, spinal cord disease, cerebral palsy, Spinal cord injury, multiple sclerosis, and brain injury. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lyvispah%" OR LOWER(tradeNames_string) LIKE "%lyvispah%" OR LOWER(drugSynonyms_string) LIKE "%lyvispah%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3627', 'tradeNames_string': 'Baclofen, Baclospas-10, Fleqsuvy, Gablofen, Kemstro, Lioresal, Lioresal intrath, Lyflex, Lyvispah, Ozobax', 'drugName': 'Baclofen', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'GABA-B receptor agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Spasticity (HP_0001257), Cannabis Dependence (EFO_0007191), Reproductive System Disease (EFO_0000512), Spinal Cord Injury (EFO_1001919), Charcot-Marie-Tooth Disease (MONDO_0015626), Hepatocellular Carcinoma (EFO_0000182), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Cocaine Dependence (EFO_0002610), Alcohol Withdrawal (EFO_0004777), Drug Dependence (EFO_0003890), Rigidity (HP_0002063), Brain Injury (MONDO_0043510), Ataxia Telangiectasia (MONDO_0008840), Gastroesophageal Reflux Disease (EFO_0003948), Alcohol Dependence (MONDO_0007079), Alcoholic Liver Cirrhosis (EFO_1000802)', 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.541 | Q22 | What is Azilect? | Azilect, also known generically as Rasagiline Mesylate, was approved by the FDA in 2006 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azilect%" OR LOWER(tradeNames_string) LIKE "%azilect%" OR LOWER(drugSynonyms_string) LIKE "%azilect%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4089', 'tradeNames_string': 'Azilect, Rasagiline mesylate', 'drugName': 'Rasagiline Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Monoamine oxidase B inhibitor', 'linkedDiseasesDrug_string': 'Multiple System Atrophy (EFO_1001050), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1464', 'tradeNames_string': '', 'drugName': 'Rasagiline', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Monoamine oxidase B inhibitor', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Amyotrophic Lateral Sclerosis (MONDO_0004976), Parkinson Disease (MONDO_0005180), Progressive Supranuclear Palsy (MONDO_0019037), Multiple System Atrophy (EFO_1001050), Restless Legs Syndrome (EFO_0004270)', 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.171 | Q22 | What is Farxiga? | Farxiga, also known generically as Dapagliflozin Propylene Glycol, was approved by the FDA in 2014 to treat heart failure and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%farxiga%" OR LOWER(tradeNames_string) LIKE "%farxiga%" OR LOWER(drugSynonyms_string) LIKE "%farxiga%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1962', 'tradeNames_string': 'Farxiga', 'drugName': 'Dapagliflozin Propylene Glycol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Sodium/glucose cotransporter 2 inhibitor', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147)', 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.453 | Q22 | What is Rhopressa? | Rhopressa, also known generically as Netarsudil Dimesylate, was approved by the FDA in 2017 to treat open-angle glaucoma and ocular hypertension. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rhopressa%" OR LOWER(tradeNames_string) LIKE "%rhopressa%" OR LOWER(drugSynonyms_string) LIKE "%rhopressa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4693', 'tradeNames_string': 'Rhopressa', 'drugName': 'Netarsudil Dimesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Rho-associated protein kinase inhibitor', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069)', 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.165 | Q22 | What is Pradaxa? | Pradaxa, also known generically as Dabigatran Etexilate, was approved by the FDA in 2010 to treat Recurrent thrombophlebitis and thrombotic disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pradaxa%" OR LOWER(tradeNames_string) LIKE "%pradaxa%" OR LOWER(drugSynonyms_string) LIKE "%pradaxa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2486', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Hematoma (EFO_0010680), Ischemic Stroke (HP_0002140), Respiratory Syncytial Virus Infection (EFO_1001413), Hemorrhage (MP_0001914), Stroke (EFO_0000712), Cadasil (Orphanet_136), Venous Thromboembolism (EFO_0004286), Thromboembolism (HP_0001907), Injury (EFO_0000546), Renal Insufficiency (HP_0000083), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 3, 'yearOfFirstApproval': 0, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_5711', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran Etexilate Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Acute Pancreatitis (EFO_1000652), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_952', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran Etexilate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Chronic Kidney Disease (EFO_0003884), Coronary Artery Disease (EFO_0001645), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Thromboembolism (HP_0001907), Venous Thrombosis (HP_0004936), Thrombotic Disease (MONDO_0000831), Renal Insufficiency (HP_0000083), Acute Pancreatitis (EFO_1000652), Prostate Adenocarcinoma (EFO_0000673), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.313 | Q22 | What is Neoprofen? | Neoprofen, also known generically as Ibuprofen Lysine, was approved by the FDA in 2006 to treat Patent ductus arteriosus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%neoprofen%" OR LOWER(tradeNames_string) LIKE "%neoprofen%" OR LOWER(drugSynonyms_string) LIKE "%neoprofen%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1446', 'tradeNames_string': 'Seractil', 'drugName': 'Dexibuprofen', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Fever (HP_0001945), Pain (EFO_0003843)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 0, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4050', 'tradeNames_string': 'Feminax express, Ibuprofen lysine, Neoprofen, Nurofen advance, Nurofen max strgth mig pain, Nurofen migraine pain, Nurofen tension headache', 'drugName': 'Ibuprofen Lysine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Patent Ductus Arteriosus (HP_0001643)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.196 | Q22 | What is Trudhesa? | Trudhesa, also known generically as Dihydroergotamine Mesylate, was approved by the FDA in 1946 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trudhesa%" OR LOWER(tradeNames_string) LIKE "%trudhesa%" OR LOWER(drugSynonyms_string) LIKE "%trudhesa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5316', 'tradeNames_string': 'D.h.e. 45, Diergo, Dihydergot, Dihydroergotamine mesylate, Tonopan, Trudhesa', 'drugName': 'Dihydroergotamine Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1946, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.485 | Q22 | What is Gelnique? | Gelnique, also known generically as Oxybutynin Chloride, was approved by the FDA in 1975 to treat overactive bladder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gelnique%" OR LOWER(tradeNames_string) LIKE "%gelnique%" OR LOWER(drugSynonyms_string) LIKE "%gelnique%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_871', 'tradeNames_string': 'Ditropan, Ditropan xl, Gelnique, Oxybutynin chloride', 'drugName': 'Oxybutynin Chloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Prostate Carcinoma (EFO_0001663)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_872', 'tradeNames_string': 'Ditropan, Ditropan xl, Gelnique, Oxybutynin chloride', 'drugName': 'Oxybutynin Chloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M2 antagonist', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Prostate Carcinoma (EFO_0001663)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.371 | Q22 | What is Tirosint-Sol? | Tirosint-Sol, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tirosint-sol%" OR LOWER(tradeNames_string) LIKE "%tirosint-sol%" OR LOWER(drugSynonyms_string) LIKE "%tirosint-sol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.389 | Q22 | What is Amitiza? | Amitiza, also known generically as Lubiprostone, was approved by the FDA in 2006 to treat Constipation, Chronic pain, irritable bowel syndrome, and constipation disorder. It is a small molecule therapy that acts as a(n) opener. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amitiza%" OR LOWER(tradeNames_string) LIKE "%amitiza%" OR LOWER(drugSynonyms_string) LIKE "%amitiza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3388', 'tradeNames_string': 'Amitiza', 'drugName': 'Lubiprostone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'opener', 'drugMechanismOfAction': 'Chloride channel protein 2 opener', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Chronic Pain (HP_0012532), Constipation (HP_0002019), Constipation Disorder (MONDO_0002203), Irritable Bowel Syndrome (EFO_0000555)', 'newLinkedTargets_string': 'CLCN2 (ENSG00000114859)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.636 | Q22 | What is Kyzatrex? | Kyzatrex, also known generically as Testosterone Undecanoate, was approved by the FDA in 2014 to treat neoplasm, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kyzatrex%" OR LOWER(tradeNames_string) LIKE "%kyzatrex%" OR LOWER(drugSynonyms_string) LIKE "%kyzatrex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugName': 'Testosterone Undecanoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.542 | Q22 | What is Lexiscan? | Lexiscan, also known generically as Regadenoson, was approved by the FDA in 2008 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lexiscan%" OR LOWER(tradeNames_string) LIKE "%lexiscan%" OR LOWER(drugSynonyms_string) LIKE "%lexiscan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5278', 'tradeNames_string': 'Lexiscan', 'drugName': 'Regadenoson', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adenosine A2a receptor agonist', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Retinal Artery Occlusion (EFO_1001154), Cardiovascular Disease (EFO_0000319), Sickle Cell Anemia (MONDO_0011382)', 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3377', 'tradeNames_string': 'Lexiscan', 'drugName': 'Regadenoson', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adenosine A2a receptor agonist', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.155 | Q22 | What is Gloperba? | Gloperba, also known generically as Colchicine, was approved by the FDA in 1961 to treat gout and familial Mediterranean fever. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gloperba%" OR LOWER(tradeNames_string) LIKE "%gloperba%" OR LOWER(drugSynonyms_string) LIKE "%gloperba%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4743', 'tradeNames_string': 'Colchicine, Colcrys, Gloperba, Mitigare', 'drugName': 'Colchicine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': "Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Vasculitis (EFO_0006803), St Elevation Myocardial Infarction (EFO_0008585), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Primary Biliary Cirrhosis (EFO_1001486), Atrial Fibrillation (EFO_0000275), Prostate Cancer (MONDO_0008315), Hypertension (EFO_0000537), Intracranial Hemorrhage (EFO_0000551), Aphthous Ulcer (EFO_0003938), Acute Coronary Syndrome (EFO_0005672), Cardiac Arrhythmia (EFO_0004269), Postpericardiotomy Syndrome (EFO_1001404), Cholangiocarcinoma (EFO_0005221), Familial Mediterranean Fever (MONDO_0018088), Asthma (MONDO_0004979), Viral Pneumonia (EFO_0007541), Proliferative Vitreoretinopathy (EFO_1001129), Myocardial Infarction (EFO_0000612), Chronic Hepatitis C Virus Infection (EFO_0004220), Gout (EFO_0004274), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Diabetic Nephropathy (EFO_0000401), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Pericarditis (EFO_0007427), Vascular Disease (EFO_0004264), Atherosclerosis (EFO_0003914), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.495 | Q22 | What is Abraxane? | Abraxane, also known generically as Paclitaxel, was approved by the FDA in 1992 to treat breast carcinoma, cancer, carcinoma, neoplasm, non-small cell lung carcinoma, breast neoplasm, undifferentiated carcinoma, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abraxane%" OR LOWER(tradeNames_string) LIKE "%abraxane%" OR LOWER(drugSynonyms_string) LIKE "%abraxane%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2013', 'tradeNames_string': 'Abraxane, Pacitaxel, Paclitaxel, Paxene, Taxol, Taxol 100', 'drugName': 'Paclitaxel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Verrucous Carcinoma (EFO_0007535), Small Cell Carcinoma (EFO_0008524), Peripheral Vascular Disease (EFO_0003875), Cervical Adenocarcinoma (EFO_0001416), Hypertension (EFO_0000537), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Testicular Neoplasm (EFO_0004281), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Mixed Neoplasm (MONDO_0021043), Anemia (Phenotype) (EFO_0004272), Undifferentiated Carcinoma (EFO_0006772), Benign Prostatic Hyperplasia (EFO_0000284), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Salivary Gland Neoplasm (EFO_0003826), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Childhood Germ Cell Tumor (MONDO_0003751), Malignant Bone Neoplasm (EFO_1000350), Thymic Carcinoma (EFO_1000576), Pain (EFO_0003843), Gastrointestinal Stromal Tumor (MONDO_0011719), Breast Ductal Adenocarcinoma (EFO_0006318), Squamous Cell Lung Carcinoma (EFO_0000708), Vaginal Cancer (MONDO_0001402), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma In Situ (MONDO_0004658), Angiosarcoma (EFO_0003968), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Bronchoalveolar Adenocarcinoma (EFO_0000308), Hypopharyngeal Carcinoma (EFO_0002938), Oropharynx Cancer (EFO_1001931), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Actinic Keratosis (EFO_0002496), Thyroid Cancer (MONDO_0002108), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Salivary Gland Cancer (MONDO_0004669), Large Cell Lung Carcinoma (EFO_0003050), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Merkel Cell Skin Cancer (EFO_1001471), Stricture (EFO_0006818), Hiv Infection (EFO_0000764), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Ischemia (EFO_0000556), Genital Neoplasm, Female (EFO_1001331), Teratoma (MONDO_0002601), Peripheral Neuropathy (EFO_0003100), Peripheral Arterial Disease (EFO_0004265), Gestational Trophoblastic Neoplasm (MONDO_0018944), Sex Cord-Stromal Tumor (EFO_1000052), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Mouth Neoplasm (EFO_0003868), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Ovarian Sex Cord-Stromal Tumor (MONDO_0021657), Female Reproductive System Neoplasm (MONDO_0021148), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Penile Cancer (MONDO_0001325), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Gallbladder Cancer (MONDO_0005411), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Allergic Disease (MONDO_0005271), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Thymoma (EFO_1000581), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Uterine Cancer (MONDO_0002715), Endometrium Neoplasm (MONDO_0021251), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Neoplasm Of Esophagus (MONDO_0021355), Metastatic Melanoma (EFO_0002617), Coronary Restenosis (EFO_0004224), Endometrial Cancer (MONDO_0011962), Neuropathy (EFO_0004149), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Vulva Cancer (MONDO_0001528), Prostate Cancer (MONDO_0008315), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Cervical Carcinoma (EFO_0001061), Oral Squamous Cell Carcinoma (EFO_0000199), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Cervical Intraepithelial Neoplasia (MONDO_0022394), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)", 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.504 | Q22 | What is Protonix? | Protonix, also known generically as Pantoprazole Sodium, was approved by the FDA in 2000 to treat Esophagitis, gastroesophageal reflux disease, and Zollinger-Ellison Syndrome. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%protonix%" OR LOWER(tradeNames_string) LIKE "%protonix%" OR LOWER(drugSynonyms_string) LIKE "%protonix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1903', 'tradeNames_string': 'Pantoprazole sodium, Protonix, Protonix iv', 'drugName': 'Pantoprazole Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Neoplasm (EFO_0000616), Fish-Eye Disease (Orphanet_79292), Zollinger-Ellison Syndrome (EFO_0007549), Gastroesophageal Reflux Disease (EFO_0003948)', 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4835', 'tradeNames_string': 'Pantoloc control, Protium, Protium i.v.', 'drugName': 'Pantoprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Bacterial Disease (EFO_0000771), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Gastrin-Producing Neuroendocrine Tumor (MONDO_0003523), Laryngopharyngeal Reflux (EFO_1001355), Fish-Eye Disease (Orphanet_79292), Acute Coronary Syndrome (EFO_0005672), Esophageal Disease (EFO_0009544), Ulcer Disease (MONDO_0043839), Peptic Ulcer (HP_0004398), Helicobacter Pylori Infectious Disease (EFO_1000961), Aspergillosis (EFO_0007157), Barrett'S Esophagus (EFO_0000280), Gastroesophageal Reflux Disease (EFO_0003948), Esophagitis (HP_0100633), Neoplasm (EFO_0000616), Zollinger-Ellison Syndrome (EFO_0007549), Gastrointestinal Hemorrhage (HP_0002239), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)", 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.230 | Q22 | What is Vimpat? | Vimpat, also known generically as Erlosamide, was approved by the FDA in 2008 to treat Seizure and epilepsy. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vimpat%" OR LOWER(tradeNames_string) LIKE "%vimpat%" OR LOWER(drugSynonyms_string) LIKE "%vimpat%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4004', 'tradeNames_string': 'Lacosamide, Vimpat', 'drugName': 'Erlosamide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Central Nervous System Cancer (EFO_0000326), Status Epilepticus (EFO_0008526), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Seizure (HP_0001250), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Amyotrophic Lateral Sclerosis (MONDO_0004976), Postherpetic Neuralgia (MONDO_0041052), Kidney Disease (EFO_0003086), Primary Erythermalgia (MONDO_0007571), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.463 | Q22 | What is Inomax? | Inomax, also known generically as Nitric Oxide, was approved by the FDA in 1999 to treat Respiratory insufficiency, respiratory system disease, pulmonary arterial hypertension, respiratory failure, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inomax%" OR LOWER(tradeNames_string) LIKE "%inomax%" OR LOWER(drugSynonyms_string) LIKE "%inomax%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2884', 'tradeNames_string': 'Genosyl, Inomax', 'drugName': 'Nitric Oxide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Soluble guanylate cyclase activator', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Infection (EFO_0000544), Pulmonary Hypertension (MONDO_0005149), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), St Elevation Myocardial Infarction (EFO_0008585), Pulmonary Embolism (EFO_0003827), Hypoxemia (EFO_0009447), Colorectal Carcinoma (EFO_1001951), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Bronchiolitis (HP_0011950), Myocardial Ischemia (EFO_1001375), Respiratory Insufficiency (HP_0002093), Tinea Pedis (EFO_0007512), Congestive Heart Failure (EFO_0000373), Persistent Fetal Circulation Syndrome (EFO_1001103), Neuropathic Pain (EFO_0005762), Brain Ischemia (MONDO_0005299), Sudden Cardiac Arrest (EFO_0004278), Acute Respiratory Distress Syndrome (EFO_1000637), Diabetic Foot (EFO_1001459), Decubitus Ulcer (EFO_0007067), Acute Myocardial Infarction (EFO_0008583), Sinusitis (EFO_0007486), Cardiac Arrest (EFO_0009492), Respiratory System Disease (EFO_0000684), Sepsis (HP_0100806), Premature Birth (EFO_0003917), Anemia (Phenotype) (EFO_0004272), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Opioid Dependence (EFO_0005611), Varicose Ulcer (EFO_1001923), Congenital Heart Disease (EFO_0005207), Dyspnea (HP_0002094), Skin Ulcer (HP_0200042), Newborn Respiratory Distress Syndrome (EFO_1000644), Ischemia Reperfusion Injury (EFO_0002687), Respiratory Failure (EFO_0009686), Cutaneous Leishmaniasis (EFO_0005046), Acute Kidney Injury (HP_0001919), Cystic Fibrosis (MONDO_0009061), Bronchopulmonary Dysplasia (MONDO_0019091), Pneumonia, Aspiration (EFO_1001399), Severe Acute Respiratory Syndrome (EFO_0000694), Hypoxia (EFO_0009444)', 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.564 | Q22 | What is Neupro? | Neupro, also known generically as Rotigotine, was approved by the FDA in 2007 to treat restless legs syndrome and Parkinson disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%neupro%" OR LOWER(tradeNames_string) LIKE "%neupro%" OR LOWER(drugSynonyms_string) LIKE "%neupro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2304', 'tradeNames_string': 'Neupro', 'drugName': 'Rotigotine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'D2-like dopamine receptor agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Stroke (EFO_0000712), Parkinson Disease (MONDO_0005180), Fibromyalgia (EFO_0005687), Restless Legs Syndrome (EFO_0004270)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.106 | Q22 | What is Posimir? | Posimir, also known generically as Bupivacaine, was approved by the FDA in 1972 to treat Hernia and pain. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%posimir%" OR LOWER(tradeNames_string) LIKE "%posimir%" OR LOWER(drugSynonyms_string) LIKE "%posimir%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5747', 'tradeNames_string': 'Anekain, Exparel, Marcaine, Posimir, Sensorcaine', 'drugName': 'Bupivacaine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel protein type IV alpha subunit blocker', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Genital Neoplasm, Female (EFO_1001331), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Hemorrhage (MP_0001914), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Urethral Stricture (HP_0012227), Pain (EFO_0003843), Cough (HP_0012735), Femoral Neck Fracture (EFO_1001792), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Shoulder Pain (HP_0030834), Injury (EFO_0000546), Hypotension (EFO_0005251), Appendicitis (EFO_0007149), Pregnancy (EFO_0002950), Musculoskeletal System Disease (EFO_0009676), Lung Disease (EFO_0003818), Hot Flashes (HP_0031217), Parathyroid Adenoma (EFO_1001087), Breast Neoplasm (EFO_0003869), Hypospadias (EFO_0004209), Post-Traumatic Stress Disorder (EFO_0001358), Headache (HP_0002315), Prostate Cancer (MONDO_0008315), Atrial Fibrillation (EFO_0000275), Breast Cancer (MONDO_0007254), Rotator Cuff Tear (EFO_1001250), Neoplasm (EFO_0000616), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Epiphora (HP_0009926), Chronic Pancreatitis (EFO_0000342), Plantar Fasciitis (EFO_1001909), Rib Fracture (EFO_0009620), Bone Fracture (EFO_0003931), Ileus (MONDO_0004567), Dupuytren Contracture (EFO_0004229), Pancreatic Carcinoma (EFO_0002618), Sinusitis (EFO_0007486), Inguinal Hernia (HP_0000023), Osteoarthritis, Hip (EFO_1000786), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Soft Tissue Sarcoma (EFO_1001968), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cleft Palate (HP_0000175), Intracranial Vasospasm (EFO_1000994), Ankle Fracture (EFO_0009615), Hiv Infection (EFO_0000764), Umbilical Hernia (HP_0001537), Pulpitis (EFO_1001139), Breech Presentation (HP_0001623), Osteoarthritis (MONDO_0005178), Hernia (HP_0100790), Non-Small Cell Lung Carcinoma (EFO_0003060), Chronic Pain (HP_0012532), Post-Operative Sign Or Symptom (EFO_0005323), Radiculopathy (MONDO_0002959), Sarcoma (EFO_0000691), Blood Coagulation Disease (EFO_0009314), Mucositis (EFO_1001898), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Ptosis (MONDO_0000728), Aortic Coarctation (EFO_1001267)', 'newLinkedTargets_string': 'SCN4A (ENSG00000007314)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.427 | Q22 | What is Kynamro? | Kynamro, also known generically as Mipomersen Sodium, was approved by the FDA in 2013 to treat cardiovascular disease and familial hypercholesterolemia. It is a oligonucleotide therapy that acts as a(n) antisense inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kynamro%" OR LOWER(tradeNames_string) LIKE "%kynamro%" OR LOWER(drugSynonyms_string) LIKE "%kynamro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3718', 'tradeNames_string': 'Kynamro', 'drugName': 'Mipomersen Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'antisense inhibitor', 'drugMechanismOfAction': 'Apo-B 100 mRNA antisense inhibitor', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124)', 'newLinkedTargets_string': 'APOB (ENSG00000084674)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.685 | Q22 | What is Zelboraf? | Zelboraf, also known generically as Vemurafenib, was approved by the FDA in 2011 to treat cancer, cutaneous melanoma, neoplasm, melanoma, and metastatic melanoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zelboraf%" OR LOWER(tradeNames_string) LIKE "%zelboraf%" OR LOWER(drugSynonyms_string) LIKE "%zelboraf%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3298', 'tradeNames_string': 'Zelboraf', 'drugName': 'Vemurafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Langerhans Cell Histiocytosis (EFO_1000318), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Central Nervous System Cancer (EFO_0000326), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Skin Carcinoma (EFO_0009259), Thyroid Cancer (MONDO_0002108), Craniopharyngioma (EFO_1000209), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Melanoma (EFO_0000756), Histiocytosis (HP_0100727)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.534 | Q22 | What is Mirapex Er? | Mirapex Er, also known generically as Pramipexole Dihydrochloride, was approved by the FDA in 1997 to treat restless legs syndrome and Parkinson disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mirapex er%" OR LOWER(tradeNames_string) LIKE "%mirapex er%" OR LOWER(drugSynonyms_string) LIKE "%mirapex er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5763', 'tradeNames_string': 'Mirapex, Mirapex Extended Release, Mirapex er, Pramipexole dihydrochloride', 'drugName': 'Pramipexole Dihydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'D2-like dopamine receptor agonist', 'linkedDiseasesDrug_string': 'Restless Legs Syndrome (EFO_0004270), Amyotrophic Lateral Sclerosis (MONDO_0004976), Bipolar Disorder (MONDO_0004985), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.75 | Q22 | What is Qvar 80? | Qvar 80, also known generically as Beclomethasone Dipropionate, was approved by the FDA in 1976 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qvar 80%" OR LOWER(tradeNames_string) LIKE "%qvar 80%" OR LOWER(drugSynonyms_string) LIKE "%qvar 80%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5013', 'tradeNames_string': 'Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe, Becloaqua 50, Becloforte, Becloforte e-breathe, Becloforte integra, Becloforte-vm, Beclomet diprop, Beclomet hayfever, Beclomist, Beclotaide, Beclovent, Becodisks, Beconase, Beconase aq, Becotide, Becotide 100, Becotide 100 e-breathe, Becotide 200, Becotide 50, Becotide 50 e-breathe, Clenil modulite, Clipper, Filair 100, Filair 50, Filair fte, Fostair, Fostair nexthaler, Nasobec aq, Nasobec hayfever, Propaderm, Propaderm fte, Propaderm-a, Propaderm-c, Pulvinal beclomet, Qnasl, Qvar 100, Qvar 100 e-breathe, Qvar 40, Qvar 50, Qvar 50 e-breathe, Qvar 80, Qvar redihaler, Rino clenil, Vancenase, Vancenase aq, Vancenase pockethaler, Vanceril, Vanceril double strength, Ventide, Vivabec, Zonivent aquanasal', 'drugName': 'Beclomethasone Dipropionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Idiopathic Pulmonary Fibrosis (EFO_0000768), Seasonal Allergic Rhinitis (EFO_0003956), Acute Graft Vs. Host Disease (EFO_0004599), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Bronchiectasis (HP_0002110), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Nasal Congestion (HP_0001742), Croup (EFO_0007227), Newborn Respiratory Distress Syndrome (EFO_1000644), Enteritis (MONDO_0043579), Folliculitis (EFO_1000702), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1976, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.118 | Q22 | What is Sorilux? | Sorilux, also known generically as Calcipotriene, was approved by the FDA in 1993 to treat psoriasis and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sorilux%" OR LOWER(tradeNames_string) LIKE "%sorilux%" OR LOWER(drugSynonyms_string) LIKE "%sorilux%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5049', 'tradeNames_string': 'Calcipotriene, Dovobet, Dovonex, Enstilar, Sorilux, Xamiol', 'drugName': 'Calcipotriene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vitamin D receptor agonist', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Localised Scleroderma (EFO_1001361), Vitiligo (EFO_0004208), Psoriasis (EFO_0000676), Squamous Cell Carcinoma (EFO_0000707), Radiodermatitis (MONDO_0043771), Atopic Eczema (EFO_0000274), Actinic Keratosis (EFO_0002496), Skin Disease (EFO_0000701), Acne (EFO_0003894), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.413 | Q22 | What is Daytrana? | Daytrana, also known generically as Methylphenidate, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daytrana%" OR LOWER(tradeNames_string) LIKE "%daytrana%" OR LOWER(drugSynonyms_string) LIKE "%daytrana%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2370', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugName': 'Methylphenidate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2371', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugName': 'Methylphenidate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.680 | Q22 | What is Levitra? | Levitra, also known generically as Vardenafil, was approved by the FDA in 2003 to treat erectile dysfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levitra%" OR LOWER(tradeNames_string) LIKE "%levitra%" OR LOWER(drugSynonyms_string) LIKE "%levitra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2264', 'tradeNames_string': 'Levitra', 'drugName': 'Vardenafil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Pulmonary Hypertension (MONDO_0005149), Ischemia Reperfusion Injury (EFO_0002687), Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Raynaud Disease (EFO_1001145), Tinnitus (HP_0000360), Cystic Fibrosis (MONDO_0009061)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4542', 'tradeNames_string': 'Levitra, Staxyn, Vardenafil hydrochloride', 'drugName': 'Vardenafil Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.122 | Q22 | What is Tabrecta? | Tabrecta, also known generically as Capmatinib Hydrochloride, was approved by the FDA in 2020 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tabrecta%" OR LOWER(tradeNames_string) LIKE "%tabrecta%" OR LOWER(drugSynonyms_string) LIKE "%tabrecta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_568', 'tradeNames_string': 'Tabrecta', 'drugName': 'Capmatinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.54 | Q22 | What is Saphris? | Saphris, also known generically as Asenapine Maleate, was approved by the FDA in 2009 to treat bipolar disorder, bipolar I disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%saphris%" OR LOWER(tradeNames_string) LIKE "%saphris%" OR LOWER(drugSynonyms_string) LIKE "%saphris%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4103', 'tradeNames_string': 'Saphris', 'drugName': 'Asenapine Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4104', 'tradeNames_string': 'Saphris', 'drugName': 'Asenapine Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.154 | Q22 | What is Colcrys? | Colcrys, also known generically as Colchicine, was approved by the FDA in 1961 to treat gout and familial Mediterranean fever. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%colcrys%" OR LOWER(tradeNames_string) LIKE "%colcrys%" OR LOWER(drugSynonyms_string) LIKE "%colcrys%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4743', 'tradeNames_string': 'Colchicine, Colcrys, Gloperba, Mitigare', 'drugName': 'Colchicine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': "Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Vasculitis (EFO_0006803), St Elevation Myocardial Infarction (EFO_0008585), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Primary Biliary Cirrhosis (EFO_1001486), Atrial Fibrillation (EFO_0000275), Prostate Cancer (MONDO_0008315), Hypertension (EFO_0000537), Intracranial Hemorrhage (EFO_0000551), Aphthous Ulcer (EFO_0003938), Acute Coronary Syndrome (EFO_0005672), Cardiac Arrhythmia (EFO_0004269), Postpericardiotomy Syndrome (EFO_1001404), Cholangiocarcinoma (EFO_0005221), Familial Mediterranean Fever (MONDO_0018088), Asthma (MONDO_0004979), Viral Pneumonia (EFO_0007541), Proliferative Vitreoretinopathy (EFO_1001129), Myocardial Infarction (EFO_0000612), Chronic Hepatitis C Virus Infection (EFO_0004220), Gout (EFO_0004274), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Diabetic Nephropathy (EFO_0000401), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Pericarditis (EFO_0007427), Vascular Disease (EFO_0004264), Atherosclerosis (EFO_0003914), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.409 | Q22 | What is Janumet? | Janumet, also known generically as Metformin Hydrochloride, was approved by the FDA in 1995 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%janumet%" OR LOWER(tradeNames_string) LIKE "%janumet%" OR LOWER(drugSynonyms_string) LIKE "%janumet%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugName': 'Sitagliptin Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1887', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1888', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial complex I (NADH dehydrogenase) inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.665 | Q22 | What is Remodulin? | Remodulin, also known generically as Treprostinil, was approved by the FDA in 2002 to treat Recurrent thrombophlebitis, pulmonary arterial hypertension, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remodulin%" OR LOWER(tradeNames_string) LIKE "%remodulin%" OR LOWER(drugSynonyms_string) LIKE "%remodulin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1758', 'tradeNames_string': 'Remodulin, Tyvaso, Tyvaso dpi', 'drugName': 'Treprostinil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid IP receptor agonist', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pulmonary Hypertension (MONDO_0005149), Primary Pulmonary Hypertension (MONDO_0001999), Ischemia Reperfusion Injury (EFO_0002687), Raynaud Disease (EFO_1001145), Chronic Obstructive Pulmonary Disease (EFO_0000341), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Persistent Fetal Circulation Syndrome (EFO_1001103), Peripheral Vascular Disease (EFO_0003875), Pulmonary Arterial Hypertension (EFO_0001361), Diabetic Foot (EFO_1001459), Type 1 Diabetes Mellitus (MONDO_0005147), Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717), Ischemia (EFO_0000556), Congenital Heart Disease (EFO_0005207)', 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.211 | Q22 | What is Copiktra? | Copiktra, also known generically as Duvelisib, was approved by the FDA in 2018 to treat chronic lymphocytic leukemia, neoplasm of mature B-cells, cancer, lymphoma, neoplasm, and follicular lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%copiktra%" OR LOWER(tradeNames_string) LIKE "%copiktra%" OR LOWER(drugSynonyms_string) LIKE "%copiktra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1892', 'tradeNames_string': 'Copiktra', 'drugName': 'Duvelisib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-gamma subunit inhibitor', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Asthma (MONDO_0004979), Neoplasm Of Mature B-Cells (EFO_0000096), Rheumatoid Arthritis (EFO_0000685), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Melanoma (EFO_0000756), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1893', 'tradeNames_string': 'Copiktra', 'drugName': 'Duvelisib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-delta subunit inhibitor', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Asthma (MONDO_0004979), Neoplasm Of Mature B-Cells (EFO_0000096), Rheumatoid Arthritis (EFO_0000685), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Melanoma (EFO_0000756), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.694 | Q22 | What is Zontivity? | Zontivity, also known generically as Vorapaxar Sulfate, was approved by the FDA in 2014 to treat myocardial infarction, stroke, and peripheral arterial disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zontivity%" OR LOWER(tradeNames_string) LIKE "%zontivity%" OR LOWER(drugSynonyms_string) LIKE "%zontivity%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_713', 'tradeNames_string': 'Zontivity', 'drugName': 'Vorapaxar Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Proteinase-activated receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Peripheral Arterial Disease (EFO_0004265), Acute Coronary Syndrome (EFO_0005672), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'F2R (ENSG00000181104)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.494 | Q22 | What is Zeposia? | Zeposia, also known generically as Ozanimod Hydrochloride, was approved by the FDA in 2020 to treat multiple sclerosis. It is a small molecule therapy that acts as a(n) modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zeposia%" OR LOWER(tradeNames_string) LIKE "%zeposia%" OR LOWER(drugSynonyms_string) LIKE "%zeposia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5399', 'tradeNames_string': 'Zeposia', 'drugName': 'Ozanimod Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor Edg-1 modulator', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301)', 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.474 | Q22 | What is Striverdi Respimat? | Striverdi Respimat, also known generically as Olodaterol Hydrochloride, was approved by the FDA in 2014 to treat chronic obstructive pulmonary disease, emphysema, and chronic bronchitis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%striverdi respimat%" OR LOWER(tradeNames_string) LIKE "%striverdi respimat%" OR LOWER(drugSynonyms_string) LIKE "%striverdi respimat%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5322', 'tradeNames_string': 'Striverdi respimat', 'drugName': 'Olodaterol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4859', 'tradeNames_string': 'Striverdi respimat', 'drugName': 'Olodaterol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Asthma (MONDO_0004979), Liver Disease (EFO_0001421), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.544 | Q22 | What is Orgovyx? | Orgovyx, also known generically as Relugolix, was approved by the FDA in 2020 to treat metastatic prostate cancer, neoplasm, and prostate adenocarcinoma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orgovyx%" OR LOWER(tradeNames_string) LIKE "%orgovyx%" OR LOWER(drugSynonyms_string) LIKE "%orgovyx%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2141', 'tradeNames_string': 'Orgovyx', 'drugName': 'Relugolix', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Pain (EFO_0003843), Metastatic Prostate Cancer (EFO_0000196), Uterine Fibroid (EFO_0000731), Endometriosis (EFO_0001065), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.9 | Q22 | What is Scenesse? | Scenesse, also known generically as Afamelanotide, was approved by the FDA in 2019 to treat erythropoietic protoporphyria. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%scenesse%" OR LOWER(tradeNames_string) LIKE "%scenesse%" OR LOWER(drugSynonyms_string) LIKE "%scenesse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6266', 'tradeNames_string': 'Scenesse', 'drugName': 'Afamelanotide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melanocortin receptor 1 agonist', 'linkedDiseasesDrug_string': 'Vitiligo (EFO_0004208), Ischemic Stroke (HP_0002140), Xeroderma Pigmentosum (MONDO_0019600), Acne (EFO_0003894), Erythropoietic Protoporphyria (MONDO_0001676), Urticaria (EFO_0005531)', 'newLinkedTargets_string': 'MC1R (ENSG00000258839)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5286', 'tradeNames_string': 'Scenesse', 'drugName': 'Afamelanotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melanocortin receptor 1 agonist', 'linkedDiseasesDrug_string': '', 'newLinkedTargets_string': 'MC1R (ENSG00000258839)', 'maxClinicalTrialPhase': -1, 'yearOfFirstApproval': 0, 'drugIsApproved': False}] | general | Similarity Search, Select | Metadata |
Q22.579 | Q22 | What is Wegovy? | Wegovy, also known generically as Semaglutide, was approved by the FDA in 2017 to treat diabetes mellitus and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%wegovy%" OR LOWER(tradeNames_string) LIKE "%wegovy%" OR LOWER(drugSynonyms_string) LIKE "%wegovy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6086', 'tradeNames_string': 'Ozempic, Rybelsus, Wegovy', 'drugName': 'Semaglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Osteopenia (HP_0000938), Alzheimer Disease (MONDO_0004975), Asthma (MONDO_0004979), Coronary Artery Disease (EFO_0001645), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.37 | Q22 | What is Adzenys Er? | Adzenys Er, also known generically as Amphetamine, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adzenys er%" OR LOWER(tradeNames_string) LIKE "%adzenys er%" OR LOWER(drugSynonyms_string) LIKE "%adzenys er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1570', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1571', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.458 | Q22 | What is Ofev? | Ofev, also known generically as Nintedanib, was approved by the FDA in 2014 to treat neoplasm and idiopathic pulmonary fibrosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ofev%" OR LOWER(tradeNames_string) LIKE "%ofev%" OR LOWER(drugSynonyms_string) LIKE "%ofev%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5928', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5929', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5930', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4523', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4524', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4525', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.142 | Q22 | What is Winlevi? | Winlevi, also known generically as Clascoterone, was approved by the FDA in 2020 to treat acne. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%winlevi%" OR LOWER(tradeNames_string) LIKE "%winlevi%" OR LOWER(drugSynonyms_string) LIKE "%winlevi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2803', 'tradeNames_string': 'Breezula, Winlevi', 'drugName': 'Clascoterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Androgen Receptor antagonist', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Acne (EFO_0003894)', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.257 | Q22 | What is Ionsys? | Ionsys, also known generically as Fentanyl, was approved by the FDA in 1968 to treat Chronic pain, cancer, neoplasm, pain, and migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ionsys%" OR LOWER(tradeNames_string) LIKE "%ionsys%" OR LOWER(drugSynonyms_string) LIKE "%ionsys%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6302', 'tradeNames_string': 'Abstral, Actiq, Breakyl, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-37, Duragesic-50, Duragesic-75, Durogesic, Durogesic dtrans, Effentora, Fencino, Fentalis reservoir, Fentanyl-100, Fentanyl-12, Fentanyl-25, Fentanyl-37, Fentanyl-50, Fentanyl-62, Fentanyl-75, Fentanyl-87, Fentora, Ionsys, Leptanal, Matrifen, Mezolar matrix, Mylafent, Opiodur, Oralet, Osmach, Osmanil, Pecfent, Recivit, Sublimaze, Subsys, Tilofyl, Victanyl, Yemex', 'drugName': 'Fentanyl', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Liver Disease (EFO_0001421), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Migraine Disorder (MONDO_0005277), Irritable Bowel Syndrome (EFO_0000555), Injury (EFO_0000546), Hypotension (EFO_0005251), Pregnancy (EFO_0002950), Gastric Cancer (MONDO_0001056), Respiratory Insufficiency (HP_0002093), Hypospadias (EFO_0004209), Bronchospasm (HP_0025428), Breast Cancer (MONDO_0007254), Neuropathic Pain (EFO_0005762), Acute Respiratory Distress Syndrome (EFO_1000637), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Interstitial Lung Disease (EFO_0004244), Morbid Obesity (EFO_0001074), Bone Fracture (EFO_0003931), Bone Metastasis (EFO_0009870), Pancreatic Carcinoma (EFO_0002618), Delirium (EFO_0009267), Subarachnoid Hemorrhage (EFO_0000713), Adenoma (EFO_0000232), Brain Injury (MONDO_0043510), Obstructive Sleep Apnea (EFO_0003918), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Neoplasm (EFO_0000616), Diabetic Neuropathy (EFO_1000783), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Abscess (EFO_0003030), Aortic Coarctation (EFO_1001267)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3916', 'tradeNames_string': 'Ionsys', 'drugName': 'Fentanyl Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.307 | Q22 | What is Locoid? | Locoid, also known generically as Hydrocortisone Butyrate, was approved by the FDA in 1982 to treat atopic eczema, skin disease, and seborrheic dermatitis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%locoid%" OR LOWER(tradeNames_string) LIKE "%locoid%" OR LOWER(drugSynonyms_string) LIKE "%locoid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1708', 'tradeNames_string': 'Acetasol hc, Acticort, Aeroseb-hc, Ala-cort, Ala-scalp, Alkindi sprinkle, Alphaderm, Anflam, Anucort-Hc, Anugesic hc, Anusol hc, Anusol plus hc, Anusol soothing relief, Anusol-Hc, Balneol-hc, Beta-hc, Calmurid hc, Canesten hc, Cetacort, Cipro hc, Cobadex, Colocort, Corlan, Cort-dome, Cortef, Cortenem, Cortenema, Cortril, Daktacort, Daktacort hydrocort, Derma care hydrocort, Dermacort, Dermaspray demang, Dioderm, Dome-cort, Econacort, Efcortelan p, Eldecort, Epicort, Eurax-hc, Eurax-hydrocort, Evacort, Exe-cort, Flexicort, Germoloids hc, Glycort, Gregoderm, H-cort, Hc #1, Hc #4, Hc (hydrocortisone), Hi-cor, Hydro-rx, Hydrocort in calamine oily, Hydrocort in cetomacrogol for a, Hydrocort in wte soft paraf, Hydrocortisone, Hydrocortisone in absorbase, Hydrocortone, Hydroderm, Hydroderm hc, Hytone, Jungle for, Locoid, Medicort, Mildison lipocream, Nogenic hc, Nutracort, Nybadex, Nystaform-hc, Otoseptil, Otosporin, Penecort, Perinal, Plenadren, Proctocort, Proctocream hc, Proctofoam hc, Proctosedyl, Quinocort, Sential hc, Stie-cort, Synacort, Terra-cortril nystatin, Texacort, Timocort, Timodine, Topisone, Tri-cicatrin, Uniroid, Uniroid hc, Xyloproct, Zenoxone', 'drugName': 'Hydrocortisone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Hemophagocytic Syndrome (MONDO_0015540), Chronic Primary Adrenal Insufficiency (MONDO_0015129), Refractory Anemia (EFO_0003802), Acute Myelomonocytic Leukemia (EFO_0000223), Atopic Eczema (EFO_0000274), Congenital Adrenal Hyperplasia (MONDO_0018479), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Primary Adrenal Insufficiency (MONDO_0015128), Viral Pneumonia (EFO_0007541), Borderline Personality Disorder (HP_0012076), Alopecia Areata (EFO_0004192), Acute Erythroleukemia (EFO_0000218), Leukemia (EFO_0000565), Adrenocortical Insufficiency (EFO_0009491), Cancer (MONDO_0004992), Obesity (EFO_0001073), Anaplastic Large Cell Lymphoma (EFO_0003032), Hypotension (EFO_0005251), Myelodysplastic Syndrome (EFO_0000198), Aging (GO_0007568), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Memory Impairment (EFO_0001072), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Hemorrhoid (EFO_0009552), Influenza (EFO_0007328), Opioid Dependence (EFO_0005611), Pancreatitis (EFO_0000278), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Myeloproliferative Disorder (EFO_0004251), Acute Monocytic Leukemia (EFO_0000221), Dermatitis (MONDO_0002406), Mast-Cell Leukemia (EFO_0007359), Psoriasis Vulgaris (EFO_1001494), Atrial Fibrillation (EFO_0000275), Herpes Labialis (EFO_1001347), Lymphoma (EFO_0000574), Fibromyalgia (EFO_0005687), Acute Megakaryoblastic Leukaemia (EFO_0003025), Central Nervous System Neoplasm (EFO_1000158), Myocardial Infarction (EFO_0000612), Alcohol Dependence (MONDO_0007079), Eczema (HP_0000964), Opioid Use Disorder (EFO_0010702), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147), Phobic Disorder (EFO_1001908), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Otitis Externa (EFO_0009560), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Eye Inflammation (EFO_0005752), Chronic Myelomonocytic Leukemia (EFO_1001779), Cardiac Arrest (EFO_0009492), Refractory Anemia With Excess Blasts (EFO_0003811), Sepsis (HP_0100806), Lymphoblastic Lymphoma (MONDO_0000873), Inflammation (MP_0001845), Nasal Congestion (HP_0001742), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Bronchopulmonary Dysplasia (MONDO_0019091), Oral Submucous Fibrosis (EFO_1001818), Hypoxia (EFO_0009444), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1952, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3811', 'tradeNames_string': 'Hydrocortisone butyrate, Locoid, Locoid c, Locoid crelo, Locoid lipocream', 'drugName': 'Hydrocortisone Butyrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Atopic Eczema (EFO_0000274), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.530 | Q22 | What is Iclusig? | Iclusig, also known generically as Ponatinib Hydrochloride, was approved by the FDA in 2012 to treat acute lymphoblastic leukemia and chronic myelogenous leukemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iclusig%" OR LOWER(tradeNames_string) LIKE "%iclusig%" OR LOWER(drugSynonyms_string) LIKE "%iclusig%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2277', 'tradeNames_string': 'Iclusig', 'drugName': 'Ponatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Thyroid Neoplasm (EFO_0003841), Lung Adenocarcinoma (EFO_0000571), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Lymphoblastic Leukemia (EFO_0000220), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6150', 'tradeNames_string': 'Iclusig', 'drugName': 'Ponatinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelogenous Leukemia (EFO_0000339)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.533 | Q22 | What is Gavreto? | Gavreto, also known generically as Pralsetinib, was approved by the FDA in 2020 to treat cancer, neoplasm, non-small cell lung carcinoma, and medullary thyroid gland carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gavreto%" OR LOWER(tradeNames_string) LIKE "%gavreto%" OR LOWER(drugSynonyms_string) LIKE "%gavreto%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2687', 'tradeNames_string': 'Gavreto', 'drugName': 'Pralsetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Medullary Thyroid Gland Carcinoma (MONDO_0015277), Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2688', 'tradeNames_string': 'Gavreto', 'drugName': 'Pralsetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Medullary Thyroid Gland Carcinoma (MONDO_0015277), Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2689', 'tradeNames_string': 'Gavreto', 'drugName': 'Pralsetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Medullary Thyroid Gland Carcinoma (MONDO_0015277), Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.374 | Q22 | What is Xiidra? | Xiidra, also known generically as Lifitegrast, was approved by the FDA in 2016 to treat eye disease and dry eye syndrome. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xiidra%" OR LOWER(tradeNames_string) LIKE "%xiidra%" OR LOWER(drugSynonyms_string) LIKE "%xiidra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2931', 'tradeNames_string': 'Xiidra', 'drugName': 'Lifitegrast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Integrin alpha-L/beta-2 (LFA-1) antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Dry Eye Syndrome (EFO_1000906), Eye Disease (EFO_0003966), Graft Versus Host Disease (MONDO_0013730)', 'newLinkedTargets_string': 'ITGAL (ENSG00000005844), ITGB2 (ENSG00000160255)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.60 | Q22 | What is Inlyta? | Inlyta, also known generically as Axitinib, was approved by the FDA in 2012 to treat cancer, clear cell renal carcinoma, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, and renal carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inlyta%" OR LOWER(tradeNames_string) LIKE "%inlyta%" OR LOWER(drugSynonyms_string) LIKE "%inlyta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4943', 'tradeNames_string': 'Inlyta', 'drugName': 'Axitinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Gastric Cancer (MONDO_0001056), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Renal Carcinoma (EFO_0002890), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Endometriosis (EFO_0001065), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Thyroid Neoplasm (EFO_0003841), Solitary Fibrous Tumor (MONDO_0016238), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Kidney Neoplasm (EFO_0003865), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Neoplasm (EFO_0000616), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Malignant Pleural Mesothelioma (EFO_0000770), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.114 | Q22 | What is Cabometyx? | Cabometyx, also known generically as Cabozantinib S-Malate, was approved by the FDA in 2012 to treat clear cell renal carcinoma, papillary renal cell carcinoma, papillary thyroid carcinoma, renal cell carcinoma, thyroid carcinoma, and thyroid cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cabometyx%" OR LOWER(tradeNames_string) LIKE "%cabometyx%" OR LOWER(drugSynonyms_string) LIKE "%cabometyx%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3579', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3580', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4806', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4807', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.604 | Q22 | What is Envarsus Xr? | Envarsus Xr, also known generically as Tacrolimus, was approved by the FDA in 1994 to treat Eczema and immune system disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%envarsus xr%" OR LOWER(tradeNames_string) LIKE "%envarsus xr%" OR LOWER(drugSynonyms_string) LIKE "%envarsus xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1130', 'tradeNames_string': 'Adoport, Advagraf, Astagraf xl, Capexion, Envarsus, Envarsus xr, Modigraf, Perixis, Prograf, Protopic, Tacni, Tacrolimus, Vivadex', 'drugName': 'Tacrolimus', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'FK506-binding protein 1A inhibitor', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Immune System Disease (EFO_0000540)', 'newLinkedTargets_string': 'FKBP1A (ENSG00000088832)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1994, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.510 | Q22 | What is Empaveli? | Empaveli, also known generically as Pegcetacoplan, was approved by the FDA in 2021 to treat immune system disease. It is a protein therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%empaveli%" OR LOWER(tradeNames_string) LIKE "%empaveli%" OR LOWER(drugSynonyms_string) LIKE "%empaveli%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4931', 'tradeNames_string': 'Empaveli', 'drugName': 'Pegcetacoplan', 'drugMolecularType': 'Protein', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Complement C3 inhibitor', 'linkedDiseasesDrug_string': 'Dense Deposit Disease (MONDO_0019736), Amyotrophic Lateral Sclerosis (MONDO_0004976), Thrombotic Microangiopathy (MONDO_0019737), Immune System Disease (EFO_0000540), Age-Related Macular Degeneration (EFO_0001365)', 'newLinkedTargets_string': 'C3 (ENSG00000125730)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.500 | Q22 | What is Invega Trinza? | Invega Trinza, also known generically as Paliperidone Palmitate, was approved by the FDA in 2009 to treat schizoaffective disorder and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%invega trinza%" OR LOWER(tradeNames_string) LIKE "%invega trinza%" OR LOWER(drugSynonyms_string) LIKE "%invega trinza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5388', 'tradeNames_string': 'Invega hafyera, Invega sustenna, Invega trinza', 'drugName': 'Paliperidone Palmitate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Schizoaffective Disorder (EFO_0005411)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5389', 'tradeNames_string': 'Invega hafyera, Invega sustenna, Invega trinza', 'drugName': 'Paliperidone Palmitate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Schizoaffective Disorder (EFO_0005411)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.266 | Q22 | What is Gilenya? | Gilenya, also known generically as Fingolimod, was approved by the FDA in 2010 to treat immune system disease. It is a small molecule therapy that acts as a(n) binding agent and agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gilenya%" OR LOWER(tradeNames_string) LIKE "%gilenya%" OR LOWER(drugSynonyms_string) LIKE "%gilenya%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4816', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'binding agent', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor binding agent', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4817', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor agonist', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4765', 'tradeNames_string': 'Gilenya', 'drugName': 'Fingolimod Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor agonist', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Breast Carcinoma (EFO_0000305), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.593 | Q22 | What is Sotylize? | Sotylize, also known generically as Sotalol Hydrochloride, was approved by the FDA in 1992 to treat Ventricular arrhythmia. It is a small molecule therapy that acts as a(n) blocker and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sotylize%" OR LOWER(tradeNames_string) LIKE "%sotylize%" OR LOWER(drugSynonyms_string) LIKE "%sotylize%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4569', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-1 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4570', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'HERG blocker', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4571', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.